

Subject: LINX Reflux Management System

Effective Date: 12/20

DESCRIPTION

According to the LINX® Reflux Management System Important Safety Information, the LINX® Reflux Management System is a laparoscopic, fundic-sparing anti-reflux procedure indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD) as defined by abnormal pH testing, and who are seeking an alternative to continuous acid suppression therapy (i.e. proton pump inhibitors or equivalent) in the management of their GERD.

DEFINITIONS

Gastroesophageal Reflux Disease (GERD): The Montreal consensus defined GERD as “a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications.”

POLICY GUIDELINES

OSU Health Plan considers magnetic sphincter augmentation using the LINX® Reflux Management System medically necessary when all of the following criteria are met:

1. 18 years of age or older; and
2. BMI is less than 35 kg/m²; and
3. Increased esophageal acid exposure on 24-hour pH monitoring; and
4. Normal esophageal motility; and
5. No previous foregut surgery; and
6. No hiatal hernia or small hiatal hernia (< 3 cm); and
7. Symptoms are moderate-to-severe according to a validated questionnaire or assessment tool (i.e., Foregut Symptom Questionnaire, Reflux Disease Questionnaire [RDQ], GERD-Health Related Quality of Life [GERD-HRQL]); and
8. Symptoms persist for at least 6 months despite maximal medical therapy, including all of the following:
 - a. Lifestyle changes:
 - i. Weight loss for patients with GERD who are overweight or have had recent weight gain
 - ii. Dietary changes (avoiding trigger foods, managing meal size and timing, etc.)
 - iii. Elevation of the head of the bed in individuals with nocturnal or laryngeal symptoms (e.g., cough, hoarseness, throat clearing)
 - b. Proton Pump Inhibitors once or twice a day for a minimum of 2 months, such as:
 - i. Omeprazole 20 mg
 - ii. Lansoprazole 30 mg
 - iii. Esomeprazole 20 mg
 - iv. Pantoprazole 40 mg
 - v. Dexlansoprazole 30 mg
 - vi. Rabeprazole 20 mg

Removal of the LINX® Reflux Management System is medically necessary for complications or failure of treatment.

EXCLUSIONS

OSU Health Plan considers the LINX® Reflux Management System contraindicated or experimental for the following indications (not all-inclusive):

- Suspected or known allergy to titanium, stainless steel, nickel or ferrous materials
- Hiatal hernia larger than 3 cm
- Barrett's esophagus
- Grade C or D esophagitis (LA classification)
- Electrical implants (pacemakers and defibrillators) or other metallic abdominal implants
- Major motility disorders
- Scleroderma
- Suspected or confirmed esophageal or gastric cancer
- Prior esophageal or gastric surgery or endoscopic intervention
- Distal esophageal motility less than 35 mmHg peristaltic amplitude on wet swallows, < 70% (propulsive) peristaltic sequences, or known motility disorder such as Achalasia, Nutcracker Esophagus, Diffuse Esophageal Spasm, or Hypertensive LES
- Symptoms of dysphagia more than once per week within the last 3 months
- Esophageal stricture or gross esophageal anatomic abnormalities (Schatzki's Ring, obstructive lesions, etc.)
- Esophageal or gastric varices
- Pregnancy
- Morbid obesity (BMI >35)
- Age < 18

PROCEDURE

Based on the available literature, the majority of patients are discharged home post-operatively within 24 – 48 hours. Therefore, if the above criteria are met, magnetic sphincter augmentation will be approved as an outpatient surgery.

Prior authorization requests should include the following medical records for review:

- Progress notes documenting symptoms, conservative treatment (including specific lifestyle changes; medication name(s), dose(s), length of trial with dates), BMI, etc.
- Questionnaires/Assessment tools (i.e., Foregut Symptom Questionnaire, Reflux Disease Questionnaire [RDQ], GERD-Health Related Quality of Life [GERD-HRQL])
- Upper endoscopy
- Esophageal pH testing
- Esophageal manometry
- Barium esophagram

CODES

Code	Code Description
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed
43285	Removal of esophageal sphincter augmentation device

REFERENCES

- Bell, R., et al. (2020). Magnetic Sphincter Augmentation Superior to Proton Pump Inhibitors for Regurgitation in a 1-Year Randomized Trial. *Clinical Gastroenterology and Hepatology*, 18, 1736-1743. doi:10.1016/j.cgh.2019.08.056
- Bonavina, L., et al. (2010). Laparoscopic Sphincter Augmentation Device Eliminates Reflux Symptoms and Normalizes Esophageal Acid Exposure: One- and 2-Year Results of a Feasibility Trial. *Annals of Surgery*, 252(5), 857-862. doi:10.1097/SLA.0b013e3181fd879b
- Bonavina, L., DeMeester, T. R., & Ganz, R. (2012). LINX™ Reflux Management System: Magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease. *Expert Rev Gastroenterol Hepatol*, 6(6), 667-674. doi:10.1586/egh.12.47
- Bonavina, L., Horbach, T., Schoppman, S. F., & DeMarchi, J. (2020). Three-year clinical experience with magnetic sphincter augmentation and laparoscopic fundoplication. *Surgical Endoscopy*. doi:10.1007/s00464-020-07792-1
- Bonavina, L., Saino, G., Lipham, J. C., & DeMeester, T. R. (2013). LINX® Reflux Management System in chronic gastroesophageal reflux: A novel effective technology for restoring the natural barrier to reflux. *Therapeutic Advances in Gastroenterology*, 6(4), 261-268. doi:10.1177/1756283X13486311
- Desart, K., Rossidis, G., Michel, M., Lux, T., & Ben-David, K. (2015). Gastroesophageal Reflux Management with the LINX® System for Gastroesophageal Reflux Disease Following Laparoscopic Sleeve Gastrectomy. *J Gastrointest Surg*, 19, 1782-1786. doi:10.1007/s11605-015-2887-z
- Fass, R. (2020, June 24). Approach to refractory gastroesophageal reflux disease in adults (N. J. Talley & S. Grover, Eds.). Retrieved December 08, 2020, from https://www.uptodate.com/contents/approach-to-refractory-gastroesophageal-reflux-disease-in-adults?sectionName=INITIAL%20ASSESSMENT&search=gerd&topicRef=2258&anchor=H18&source=see_link#H18
- Hawasli, A., Sadoun, M., Meguid, A., Dean, M., Sahly, M., & Hawasli, B. (2019). Laparoscopic placement of the LINX® system in management of severe reflux after sleeve gastrectomy. *The American Journal of Surgery*, 217, 496-499. doi:10.1016/j.amjsurg.2018.10.040
- Hiltz, S., Black, E., Modlin, I., Lane, G., Johnson, S., Schoenfeld, P., Allen, J. & Brill, J. (2008). American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. *Gastroenterology*, 135, 1383-1391. doi:10.1053/j.gastro.2008.08.045
- Johnson & Johnson. (2020). LINX® Reflux Management System Important Safety Information. Retrieved December 07, 2020, from https://www.jnjmedicaldevices.com/en-US/treatment/LINX-reflux-surgery?utm_source=linxforlife.com&utm_medium=referral&utm_campaign=ethicon-linxforlife-about-linx
- Kahrilas, P. J. (2020, April 1). Medical management of gastroesophageal reflux disease in adults (N. J. Talley & S. Grover, Eds.). Retrieved December 08, 2020, from https://www.uptodate.com/contents/medical-management-of-gastroesophageal-reflux-disease-in-adults?search=gerd&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#H102009998

- Kirkham, E. N., Main, B. G., Jones, K. J., Blazeby, J. M., & Blencowe, N. S. (2020). Systematic review of the introduction and evaluation of magnetic augmentation of the lower oesophageal sphincter for gastro-oesophageal reflux disease. *British Journal of Surgery*, *107*, 44-55. doi:10.1002/bjs.11391
- Lipham, J. C., et al. (2012). The LINX reflux management system: Confirmed safety and efficacy now at 4 years. *Surg Endosc*, *26*, 2944-2949. doi:10.1007/s00464-012-2289-1
- Louie, B. E., et al. (2019). Objective Evidence of Reflux Control After Magnetic Sphincter Augmentation: One Year Results From a Post Approval Study. *Annals of Surgery*, *270*(2), 302-308. doi:10.1097/SLA.0000000000002789
- Pandolfino, J., Lipham, J., Ferko, N., Hogan, A., Qadeer, R., Chawla, A., & Ghosh, S. (2019). Budget impact analysis of LINX reflux management system for the treatment of medication-refractory mechanical gastroesophageal reflux disease: A U.S. payer perspective [Abstract]. *Value in Health*, *22*, 2nd ser., S179-S179.
- Schizas, D., et al. (2020). LINX® reflux management system to bridge the “treatment gap” in gastroesophageal reflux disease: A systematic review of 35 studies. *World J Clin Cases*, *8*(2), 294-305. doi:10.12998/wjcc.v8.i2.294
- Schwaitzberg, S. (2020, February 12). Surgical management of gastroesophageal reflux in adults (B. F. Louie, N. J. Talley, & W. Chen, Eds.). Retrieved December 08, 2020, from https://www.uptodate.com/contents/surgical-management-of-gastroesophageal-reflux-in-adults?search=gerd%20surgery&source=search_result&selectedTitle=1~150&us_age_type=default&display_rank=1#H1035695800
- Schwameis, K., et al. (2018). Results of Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease. *World J Surg*, *42*, 3263-3269. doi:10.1007/s00268-018-4608-8
- Skubleny, D., et al. (2017). LINX magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: A systematic review and meta-analysis. *Surg Endosc*, *31*, 3078-3084. doi:10.1007/s00464-016-5370-3
- Telem, D., Wright, A., Shah, P., & Hutter, M. (2017, March 13). SAGES Technology and Value Assessment Committee (TVAC) Safety and Effectiveness Analysis: LINX® Reflux Management System (Torax Medical, Inc.). Retrieved December 07, 2020, from <https://www.sages.org/publications/tavac/tavac-safety-and-effectiveness-analysis-linx-reflux-management-system/#:~:text=The%20LINX%20System%20is%20indicated,performed%20laparoscopically%20under%20general%20anesthesia.>
- Torax Medical. (2012, March). LINX® Reflux Management System. Retrieved December 07, 2020, from https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100049c.pdf
- Zadeh, J., Andreoni, A., Treitl, D., & Ben-David, K. (2018). Spotlight on the Linx™ Reflux Management System for the treatment of gastroesophageal reflux disease: Evidence and research. *Medical Devices: Evidence and Research*, *11*, 291-300.